MABPHARM LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.425 HKD | 0.00% |
|
-5.56% | -7.61% |
| Mar. 26 | Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 10 | Livzon Pharma Recognizes Credit, Asset Impairments | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Mabpharm Ltd is China-based company mainly engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Company's main products include omalizumab (CMAB007), cetuximab (CMAB009) and infliximab (CMAB008). The Company mainly conducts its businesses in China market.
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -7.61% | 224M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.89% | 21.66B | |
| -18.35% | 20.77B | |
| -8.82% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- 2181 Stock
- News Mabpharm Limited
- Mabpharm : Drug for Autoimmune Diseases Wins Marketing Approval in China; Shares Jump 5%
